Trivalent rHA Dose Escalation Study in Elderly Subjects

ClinicalTrials.gov ID: NCT00170443

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00170443. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:17 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Evaluation of the Reactogenicity and Immunogenicity of Different Doses of Intramuscular Trivalent Baculovirus-expressed Influenza HA Vaccine in Healthy Elderly Adults

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will compare the safety and immunogenicity of three different dose levels of an experimental recombinant influenza HA protein vaccine to a standard inactivated influenza vaccine in heallthy elderly subjects ages 65-80. Blood and nasal secretions for assessment of antibody responses will be obtained from all subjects prior to and one month after vaccination.

Study identification

NCT ID: NCT00170443
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Enrollment: 399 participants

Conditions and interventions

Conditions

Influenza

Interventions

rHAO Trivalent Influenza Vaccine Biological

Biological

Eligibility (public fields only)

Age range: 65 Years to 80 Years
Sex: All
Healthy volunteers: Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Not listed
Primary completion: Not listed
Completion: Jun 2004 (Type not available)
Last update posted: Aug 12, 2011

Ends 2004

United States locations

U.S. sites: 3
U.S. states: 3
U.S. cities: 3

Facility	City	State	ZIP	Site status
University of Rochester	Rochester	New York	14642	—
Cincinnati Children's Hospital Medical Center	Cincinnati	Ohio	45229	—
Baylor College of Medicine	Houston	Texas	77030	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00170443, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 12, 2011 · Synced Nov 15, 2026